Ultrasound Screening for Developmental Dysplasia of the Hip in Newborns

Not Applicable

Completed

• Conditions: Hip Dysplasia
• Interventions: Procedure: hip ultrasound

• Registration Number: NCT01818934
• Lead Sponsor: University of Bergen

Brief Summary

The aim of the randomized controlled trial was to determine whether the addition of a general or of a selective ultrasound screening program resulted in more appropriate criteria for treatment and a reduced prevalence of late DDH compared with clinical examination alone.

Detailed Description

This is a retrospective registration of a RCT carried out in 1988-90, with a IRB approved follow-up at skeletal maturity carried out in 2007-09. Both the RCT and the follow-up study were carried out in the same institution, by the same PI (Prof. Karen Rosendahl) and her co-workers.

Detailed information is published in the following paper:

Rosendahl K, Markestad T, Lie RT. Ultrasound screening for developmental dysplasia of the hip in the neonate: the effect on treatment rate and prevalence of late cases. Pediatrics 1994;94:47-52.

A sample of the initial RCT was invited for a maturity review/follow-up at skeletal maturity.

The follow-up at skeletal maturity is called:

Radiological indices of hip dysplasia and osteoarthritis at skeletal maturity in the Bergen Birth Cohort. Associations with neonatal hip dysplasia, childhood growth and genetic predisposition

and is included in the approval by the Regional Ethical Committee for Medical and Health Research (No 3.2006.144). All participants of the follow-up study gave written informed consent according to the 1964 Declaration of Helsinki.

The follow-up had the following main aims:

1) estimate the prevalence of radiologically defined hip dysplasia, femoroacetabular impingement and osteoarthritis assessed at skeletal maturity 2)report the frequency of 4 longitudinal dysplasia phenotypes based on sonographic assessments in the newborn and radiological assessments at skeletal maturity 3)investigate associations of dysplasia as defined in 1 and 2 above in univariate and multivariate models with clinically assessed hip joint mobility/joint hypermobility, weight, height and body mass index (BMI) at age 18/19 years, prepubertal weight, height and BMI trajectories using data from child health records, first degree family history of hip dysplasia with or without hip arthroplasty, perinatal factors, measures of OA including minimum joint space, acetabular depth ratio and reported hip pain 5) establish a genetic resource by obtaining and archiving salivary DNA samples.

Study Timeline

• Study Start: 1988-01
• Primary Completion: 1990-06
• Study Completion: 2009-03
• Status Verified: 2013-03
• Study First Submitted: 2013-03-21
• Study First Submitted QC: 2013-03-21
• Last Update Submitted: 2013-03-21
• Study First Posted: 2013-03-27
• Last Update Posted: 2013-03-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11925

Inclusion Criteria

• all babies born at our institution during 1/1988-06/1990

Exclusion Criteria

• low birthweight <1500 grams, severe malformations, death within first month

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
selective hip ultrasound screening	hip ultrasound	all children classified at increased risk, based on clinical findings and/or risk factors (breech presentation, family history, foot deformity)received a hip ultrasound at birth, in addition to expert clinical screening
expert clinical exam only	hip ultrasound	all babies assigned to this group had expert clinical examination only, no hip ultrasound
universal hip ultrasound screening	hip ultrasound	All newborns assigned to this arm received hip ultrasound at birth in addition to expert clinical examination

Primary Outcome Measures

Name	Time	Method
prevalence of DDH detected after newborn period	20 years	prevalence of late cases of DDH, detected after newborn period (after first month of age, including in childhood as assessed in original RCT during 1988-90, with a minimum follow-up time of 27 months, and also at skeletal maturity, as assessed in follow-up study during 2007-09.

Secondary Outcome Measures

Name	Time	Method
treatment rate	20 years	abduction treatment and/or surgery during infancy, later childhood and skeletal maturity

Trial Locations

Locations (1)

Haukeland University Hospital; 🇳🇴 Bergen, Norway